Advertisement
BIIB vs EDAP
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and EDAP is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileEDAP’s FA Score has 0 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- EDAP’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 6 TA indicator(s) are bullish while EDAP’s TA Score has 4 bullish TA indicator(s).
- BIIB’s TA Score: 6 bullish, 3 bearish.
- EDAP’s TA Score: 4 bullish, 5 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а -6.59% price change this week, while EDAP (@Medical Distributors) price change was -0.58% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.27%. For the same industry, the average monthly price growth was +5.99%, and the average quarterly price growth was +9.00%.
The average weekly price growth across all stocks in the @Medical Distributors industry was +1.14%. For the same industry, the average monthly price growth was -0.76%, and the average quarterly price growth was -5.89%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 23, 2025.
EDAP is expected to report earnings on Aug 20, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (-1.27% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Medical Distributors (+1.14% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
| BIIB | EDAP | BIIB / EDAP | |
| Capitalization | 31.3B | 282M | 11,099% |
| EBITDA | 2.04B | -18.39M | -11,083% |
| Gain YTD | -17.238 | -22.624 | 76% |
| P/E Ratio | 26.95 | 100.00 | 27% |
| Revenue | 9.84B | 60.4M | 16,285% |
| Total Cash | 1.05B | 43.5M | 2,414% |
| Total Debt | 7.34B | 8.42M | 87,108% |
BIIB | EDAP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 71 | 97 | |
PRICE GROWTH RATING 1..100 | 62 | 87 | |
P/E GROWTH RATING 1..100 | 96 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BIIB's Valuation (88) in the Biotechnology industry is in the same range as EDAP (99). This means that BIIB’s stock grew similarly to EDAP’s over the last 12 months.
BIIB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDAP (100). This means that BIIB’s stock grew similarly to EDAP’s over the last 12 months.
BIIB's SMR Rating (71) in the Biotechnology industry is in the same range as EDAP (97). This means that BIIB’s stock grew similarly to EDAP’s over the last 12 months.
BIIB's Price Growth Rating (62) in the Biotechnology industry is in the same range as EDAP (87). This means that BIIB’s stock grew similarly to EDAP’s over the last 12 months.
BIIB's P/E Growth Rating (96) in the Biotechnology industry is in the same range as EDAP (100). This means that BIIB’s stock grew similarly to EDAP’s over the last 12 months.
| BIIB | EDAP | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 71% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 70% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 84% |
| Advances ODDS (%) | 9 days ago 54% | 21 days ago 76% |
| Declines ODDS (%) | 6 days ago 70% | 6 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 60% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 55% | 2 days ago 83% |
Advertisement
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | -3.42% | ||
| AMGN - BIIB | 52% Loosely correlated | -1.86% | ||
| PFE - BIIB | 48% Loosely correlated | -1.64% | ||
| NVS - BIIB | 46% Loosely correlated | -1.42% | ||
| SNY - BIIB | 43% Loosely correlated | -2.41% | ||
| GSK - BIIB | 43% Loosely correlated | -1.90% | ||
More | ||||
EDAP and
Correlation & Price change
A.I.dvisor tells us that EDAP and AORT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EDAP and AORT's prices will move in lockstep.
| Ticker / NAME | Correlation To EDAP | 1D Price Change % | ||
|---|---|---|---|---|
| EDAP | 100% | -1.72% | ||
| AORT - EDAP | 29% Poorly correlated | +3.62% | ||
| AVNS - EDAP | 21% Poorly correlated | -0.74% | ||
| SRDX - EDAP | 21% Poorly correlated | -2.75% | ||
| UFPT - EDAP | 20% Poorly correlated | -0.72% | ||
| SENS - EDAP | 20% Poorly correlated | -2.50% | ||
More | ||||